forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, with analysts and investors describing the results as "good enough" to ease nerves about stiff ...

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid ...

Sold under brand names including Wegovy and Ozempic ... of alcohol that people consumed,” says Hendershot. “The results are promising,” says Rong Xu at Case Western Reserve University ...

forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, with analysts and investors describing the results as "good enough" to ease nerves about stiff competition ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current best-selling drug in this area, Wegovy ... loss of 22% after 36 weeks.

The drugs were originally developed to treat type 2 diabetes, but have revolutionised the treatment of obesity after Wegovy was licensed ... higher than the year before. Senior author Klara ...

Novo Nordisk's U.S.-listed shares rose 5% in intraday trading after the Ozempic and Wegovy maker's better-than-estimated quarterly results offset slower 2025 sales growth projections amid ...

Obesity drug maker Novo Nordisk NVO-N forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, with analysts and investors describing the results as “good ...

forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, with analysts and investors describing the results as "good enough" to ease nerves about stiff ...